title: CRIMALDDI: a co-ordinated, rational, and integrated effort to set logical priorities in anti-malarial drug discovery initiatives.
abstract: Despite increasing efforts and support for anti-malarial drug R&D, globally anti-malarial drug discovery and development remains largely uncoordinated and fragmented. The current window of opportunity for large scale funding of R&D into malaria is likely to narrow in the coming decade due to a contraction in available resources caused by the current economic difficulties and new priorities (e.g. climate change). It is, therefore, essential that stakeholders are given well-articulated action plans and priorities to guide judgments on where resources can be best targeted.The CRIMALDDI Consortium (a European Union funded initiative) has been set up to develop, through a process of stakeholder and expert consultations, such priorities and recommendations to address them. It is hoped that the recommendations will help to guide the priorities of the European anti-malarial research as well as the wider global discovery agenda in the coming decade.
authors.affiliation: Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK.
authors.forename: Ian C
authors.initials: IC
authors.lastname: Boulton
authors.forename: Solomon
authors.initials: S
authors.lastname: Nwaka
authors.forename: Ian
authors.initials: I
authors.lastname: Bathurst
authors.forename: Michael
authors.initials: M
authors.lastname: Lanzer
authors.forename: Donatella
authors.initials: D
authors.lastname: Taramelli
authors.forename: Henri
authors.initials: H
authors.lastname: Vial
authors.forename: Christian
authors.initials: C
authors.lastname: Doerig
authors.forename: Kelly
authors.initials: K
authors.lastname: Chibale
authors.forename: Steve A
authors.initials: SA
authors.lastname: Ward
mesh_terms: D000962:Antimalarials / Q000191:economics* / Q000627:therapeutic use; D055808:Drug Discovery / Q000191:economics* / Q000458:organization & administration; D004351:Drug Resistance; D005062:European Union; D006291:Health Policy; D006292:Health Priorities; D006801:Humans; D008288:Malaria / Q000188:drug therapy / Q000517:prevention & control; D010961:Plasmodium / Q000187:drug effects; D012106:Research / Q000191:economics* / Q000639:trends
chemical_list: D000962:Antimalarials